Retatrutide has no legitimate price. It is not FDA-approved, Lilly plans to file with the FDA in early 2027, and the only lawful access is a clinical trial, where it costs participants $0.[7] For comparison, approved GLP-1s bought direct from their makers cost about $149 to $449 a month in cash in October 2026, depending on drug and dose.[4][5]
“How much does retatrutide cost?” is a fair question with an uncomfortable answer: it does not have a cost, because it does not yet have a price. Retatrutide is investigational — Eli Lilly’s once-weekly triple agonist of the GIP, GLP-1 and glucagon receptors, now reporting Phase 3 TRIUMPH results and not approved by the FDA or any other regulator.[3] No approval means no list price, no pharmacy line item, and no legitimate retail market. This page is the honest economics: why there is no real price, what the only free-and-legal route actually is, why the numbers circulating online are not a price at all, and — as a proxy for what a real GLP-1 costs — approximate figures for the approved drugs you can buy today. For the separate question of sourcing, legality and safety, see where to buy retatrutide; this page stays on money.
Why is there no retatrutide price yet?
A price is the end of a long chain: a drug clears human trials for a defined use, earns FDA approval, is manufactured under Good Manufacturing Practice, and only then gets a list price and a pharmacy shelf. Retatrutide has not reached the end of that chain. Its Phase 3 trials are reporting and Lilly says it plans to submit an application to the FDA in the first quarter of 2027,[7] but until it is approved it cannot be prescribed for general use, cannot be dispensed by a pharmacy, and has no manufacturer list price to quote.[3] You can confirm the status yourself — it does not appear as an approved product in Drugs@FDA.[3] Until that changes, any number attached to “retatrutide cost” is either a projection or a gray-market figure, not a real price.
The demand driving the question is genuine, and it is worth understanding where it comes from. In the original 48-week Phase 2 obesity trial of 338 adults, the highest dose produced mean weight loss of roughly 24%[1] — and in May 2026 Lilly reported the first Phase 3 obesity trial, TRIUMPH-1, with mean weight loss of 28.3% on 12 mg versus 2.2% on placebo at 80 weeks (company-reported topline results).[6] A parallel Phase 2 trial also showed substantial glucose and weight effects in type 2 diabetes.[2] That is why people are already shopping for it. We walk through those numbers and their limits in our retatrutide evidence review. But a striking trial result is a statement about a research molecule, not a receipt — impressive efficacy and an actual purchasable price are different things.
Can you get retatrutide for free in a clinical trial?
Yes. There is exactly one lawful way to receive retatrutide today, and it is free. Clinical trial participants are given the study drug and medical monitoring at no charge — trials do not sell the investigational medicine to enrollees. So the only “price” that legitimately exists for retatrutide right now is zero dollars, paid inside a supervised study rather than at a checkout. Enrollment is not guaranteed, trials have strict eligibility criteria, and many are placebo-controlled, so this is access rather than a shopping option — the mechanics of finding and joining a study are covered in where to buy retatrutide. The point for a cost page is simply this: the legal route is not expensive, it is free.
Why the “research chemical” number is not a price
Search the drug’s name and you will find vials advertised at what looks like a concrete cost — often a few hundred dollars for a multi-week “research” supply. Treating that as retatrutide’s price is the core mistake this page exists to correct. A price, in any meaningful sense, buys a known quantity of a verified product with someone accountable for it. The gray-market figure buys none of that: the vial is not manufactured, tested, or labeled for human use, so what you are actually paying for is unknowable purity, unknowable potency, no sterility guarantee, and no clinician — and using it as a drug is illegal.
There is also a cost these listings never print: retatrutide’s gastrointestinal and heart-rate effects were dose-related even under trial supervision,[1] and self-dosing an unverified vial removes the one person — a physician — whose job is to manage them. If dosing is what you are trying to reverse-engineer from a purchase, our retatrutide dosage and retatrutide side effects explainers exist precisely to show why that is a research question, not a budgeting one.
What does an approved GLP-1 cost instead?
If the underlying goal is weight loss and the real question is “what will an effective GLP-1 cost me,” the honest answer is to price the drugs that are actually approved and obtainable. These are the manufacturers' own figures as of October 2026; they move often, so verify the current figure before you budget:
- Branded list price: Zepbound (tirzepatide) and Wegovy (semaglutide) carry list prices of roughly $1,000 or more per month in 2026. Novo Nordisk has announced that Wegovy's list price falls to $675 a month on January 1, 2027.[8] Almost no one on the right route pays the full sticker, but it is the ceiling.
- Manufacturer self-pay: paying cash through the makers’ own channels is much cheaper. Lilly sells Zepbound vials and KwikPen for $299 (2.5 mg), $399 (5 mg) and $449 (7.5 mg and up, with on-time refills).[4] Novo sells Wegovy pens for $349 a month ($399 for the 7.2 mg dose) and Wegovy pills from $149 to $299 by dose.[5]
- With covered commercial insurance (approximate): a plan that covers the drug plus a manufacturer savings card can bring the monthly copay down to as little as tens of dollars, though caps and eligibility rules apply.[4]
For the full, dose-by-dose breakdown of these routes and the tradeoffs between them, our cheapest tirzepatide guide is the companion to this page. The takeaway: a real, approved GLP-1 has a real, knowable cost — which is exactly what retatrutide lacks.
What might retatrutide cost if it is approved?
No one can quote a future price, but the closest guide is how Lilly and Novo Nordisk price their current GLP-1s. Both Zepbound and Wegovy entered the U.S. market with list prices in the four figures per month, and both makers now also sell direct to cash-paying patients in the low hundreds.[4][5] The list-price band is also moving: Novo has announced a $675 monthly list price for Wegovy from January 2027.[8] A reasonable expectation is that an approved retatrutide would launch with a high list price and a manufacturer self-pay option, with what patients actually pay decided — as it is for every drug in this class — by insurance coverage, self-pay channels, and savings cards rather than by the sticker. That is a projection, not a promise; pricing will depend on the label, competition, and the payer landscape at the time of approval.
The honest bottom line
Retatrutide does not have a cost because it does not yet have a legitimate market. The only lawful access is free, inside a clinical trial; the dollar figures floating around the gray market are not a price but a gamble on an unregulated vial; and the only trustworthy numbers in this whole space belong to the drugs that are already approved — roughly a few hundred to a thousand-plus dollars a month depending on route and coverage. If you want the science behind the hype, read the Phase 2 evidence. If you want something you can actually price and buy today, look at what an approved GLP-1 costs. What you should not do is mistake a checkout-page number for the price of a medicine that does not have one yet.